Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

6.270
-0.535-7.86%
Volume:26.32M
Turnover:183.97M
Market Cap:2.38B
PE:-6.73
High:8.270
Open:7.825
Low:6.250
Close:6.805
52wk High:22.560
52wk Low:5.350
Shares:380.07M
HK Float Shares:375.46M
Volume Ratio:7.09
T/O Rate:7.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.932
ROE:-70.66%
ROA:-28.19%
PB:7.84
PE(LYR):-6.73
PS:19120.63

Loading ...

Strategic Collaboration Sees Qilu Invest RMB 400 Million in TYK MEDICINES-B for TY-9591 Development and Commercialization

Stock News
·
Jul 21

TYK Medicines Prices Private Placement of 63,222,744 H Shares at HK$ 7.3 Each

Reuters
·
Jul 21

Tyk Medicines - to Receive Aggregate Upfront Payment of Rmb700 Mln Plus Potential Milestone Payments

THOMSON REUTERS
·
Jul 21

Tyk Medicines - Co Enters License and Collaboration Agreement with Qilu for Ty-9591 in China

THOMSON REUTERS
·
Jul 21

Hong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results

Stock News
·
Jul 21

TYK MEDICINES-B Shares Surge Over 15% on Upcoming Commercialization of TY-9591 and Positive Clinical Data for Edotinib

Stock News
·
Jul 14

TYK MEDICINES-B Shares Surge Over 6% on Positive Clinical Data for Brain Metastasis Drug, Anticipated Q3 Launch

Stock News
·
Jul 08

TYK Medicines Convenes 15 July 2026 EGM to Secure Share-Issuance Mandate

Bulletin Express
·
Jun 29

TYK Medicines Seeks Shareholders’ Approval for 20% General Share Issuance Mandate

Bulletin Express
·
Jun 29

TYK Medicines Announces Extraordinary General Meeting

Reuters
·
Jun 29

TYK Medicines Sets 10–15 July 2026 Book Closure to Determine EGM Voting Entitlements

Bulletin Express
·
Jun 24

TYK Medicines shareholders pass Articles of Association amendments at AGM

Reuters
·
Jun 23

TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule

Bulletin Express
·
Jun 02

Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases

Stock News
·
Jun 01

TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases

Bulletin Express
·
May 31

Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO

Stock News
·
May 31

TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases

Reuters
·
May 31

TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election

Bulletin Express
·
May 22

TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM

Bulletin Express
·
May 22

Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop

Simply Wall St.
·
May 14